We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure (FLOURISH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03360448
Recruitment Status : Not yet recruiting
First Posted : December 4, 2017
Last Update Posted : January 9, 2018
Information provided by (Responsible Party):
Renova Therapeutics

Brief Summary:
To determine the safety and efficacy of an intracoronary injection of adenovirus 5 encoding human adenylyl cyclase 6 (RT-100) in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) in a Phase 3 clinical trial.

Condition or disease Intervention/treatment Phase
Heart Failure Drug: Ad5.hAC6 Drug: Placebo Phase 3

Detailed Description:
This is a randomized, placebo-controlled, double-blinded Phase 3 clinical trial using a one-time intracoronary injection of Ad5.hAC6 (or placebo) to determine safety and efficacy in patients with documented HFrEF.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 536 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-Blind
Primary Purpose: Treatment
Official Title: Randomized, Phase 3, Placebo-Controlled Double-Blind, Multicenter Trial of a One Time Intracoronary Administration of Ad5.hAC6 Gene Transfer for Patients With Reduced Left Ventricular Heart Failure
Anticipated Study Start Date : February 2018
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Experimental
Ad5.hAC6: Intracoronary delivery of adenovirus encoding human adenylyl cyclase type 6
Drug: Ad5.hAC6
1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
Other Name: RT-100
Placebo Comparator: Placebo Comparator
Placebo: Intracoronary delivery of formulation buffer ( 3% sucrose)
Drug: Placebo
1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
Other Name: 3% sucrose

Primary Outcome Measures :
  1. Heart Failure Hospitalizations [ Time Frame: Baseline to 12 months ]
    Reduce the event rate of all (first and repeat) heart failure hospitalizations

Secondary Outcome Measures :
  1. Cardiovascular (CV) Death [ Time Frame: Baseline to 12 months ]
    Reduce the event rate of cardiovascular (CV) death

  2. All Cause Death [ Time Frame: Baseline to 12 months ]
    Reduce the event rate of death (regardless of cause)

  3. New York Heart Association (NYHA) Functional Classification [ Time Frame: Baseline to 12 months ]
    Improve NYHA functional classification

  4. All Heart Failure (HF) Events [ Time Frame: Baseline to 12 months ]
    Reduce the event rate of all heart failure (HF) events

Other Outcome Measures:
  1. Echocardiographic Parameters [ Time Frame: Baseline to 12 months ]
    Improve echocardiographic parameters of left ventricular systolic and diastolic functions.

  2. Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: Baseline to 12 months ]
    Improve clinical summary score for heart failure (HF) symptoms and physical limitations as assessed by KCCQ. Scores will be calculated according to the guidance provided by CV Outcomes Inc.

  3. Six Minute Walk Distance [ Time Frame: Baseline to 12 months ]
    Improve the six-minute walk distance (6MWD) using the standard according to the American Thoracic Society March 2002 Guidelines using a 100 foot hallway or corridor

  4. Borg Dyspena Score [ Time Frame: Baseline to 12 months ]
    Improve the Borg dyspnea score. The Borg Scale will be used (0-10, 0 = nothing at all, 10 = very, very severe)

  5. NT-proBNP [ Time Frame: Baseline to 3 and 12 months ]
    Improve N-terminal pro brain natriuretic peptide (NT-proBNP)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18 to 80 years, inclusive, with history of heart failure (HF).
  2. Current HF symptoms with NYHA Functional Classification Class II to IV (inclusive) at Screening (Visit 1).
  3. Currently receiving optimally tolerated standard of care HF medical therapy as defined by the American Heart Association (AHA)/American College of Cardiology (ACC) Heart Failure guidelines and Focused Update along with an angiotensin converting enzyme inhibitor (ACEi)/angiotensin II receptor blockers (ARB), diuretics and sacubitril/valsartan for 4 weeks or longer, without change in drug therapy or dosage regimen, prior to Visit 1 (and continued same HF therapy through Visit 2).
  4. Left Ventricular Ejection Fraction (LVEF) ≥ 10 to ≤ 35% as determined by Screening echocardiogram (ECHO).
  5. NT pro BNP ≥ 400 pg/mL.
  6. If subject has had coronary artery bypass surgery, then at least one conduit must be patent and therefore be amendable for test article.
  7. Women of child bearing capacity must have a negative pregnancy test before 2 days of test article administration and must not be currently breastfeeding or nursing, and female and male patients must be willing to use birth control for 12 weeks after test article administration if the female partner is of child bearing capacity. Acceptable methods of effective birth control include total sexual abstinence; a condom with spermicide (men) in combination with barrier methods (diaphragm, cervical cap or cervical sponge); hormonal birth control (oral or injectable contraceptives); intrauterine devices; or surgical sterilization (vasectomy and testing that shows there is no sperm in the semen for men and bilateral tubal ligation +/- oophorectomy for women).
  8. Willing to provide informed consent consistent with International Conference on Harmonisation Good Clinical Practices.

Exclusion Criteria:

  1. Use of intravenous (IV) vasodilatory or inotropic therapy within 24 hours prior to Visit 2.
  2. Unstable angina within 3 months of Visit 1.
  3. Coronary revascularization planned or predicted within 6 months prior to Visit 1.
  4. Subjects who are candidates for revascularization are not considered appropriate for this trial; therefore, if a subject has Ischemia of viable myocardium > 15% and is a candidate for revascularization, this subject would not be eligible to participate in this trial.
  5. Myocardial infarction within 6 months prior to Screening (Visit 1). Myocardial infarction is defined by documented evidence of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin) with at least one value above the 99th percentile upper reference limit, and either ischemic symptoms, electrocardiogram changes, imaging evidence of loss of viable myocardium or new regional wall motion abnormality, or identification of an intracoronary thrombus by coronary angiography.
  6. Thrombocytopenia (< 100,000 platelets/µL) or bleeding diathesis.
  7. Stroke or transient ischemic attack within 6 months prior to Screening (Visit 1).
  8. Use of sodium-glucose co-transporter 2 inhibitors used to treat type 2 diabetes mellitus.
  9. Cardiac:

    1. Biopsy documenting reversible cause of cardiomyopathy within 6 months of Visit 1 (Screening) if available as part of patient's prior cardiac history.
    2. Acute cardiac decompensation.
    3. If coronary angiogram within 6 months, with a presence of untreated severe three vessel coronary disease or unprotected left main coronary artery disease or coronary anatomy unsuitable for study procedure (eg, arterial tortuosity, etc) prior to Randomization (Visit 2).
    4. Use of IV diuretics within 12 hours of Randomization (Visit 2).
    5. Hemodynamically significant untreated valvular heart disease based on the AHA/ACC Valvular Heart Disease Guidelines.
    6. Current evidence of restrictive, peripartum, viral, infectious, infiltrative, or inflammatory cardiomyopathy.
    7. Significant pericardial effusion at Screening (Visit 1) or at the time of test article administration.
    8. Current untreated ventricular arrhythmias.
    9. Currently awaiting planned heart transplantation or ventricular assist device.
    10. Congenital heart disease (other than small or hemodynamically non significant ventricular septal defect or atrial septal defect).
    11. Device therapy as noted below:

    i. Cardiac resynchronization therapy (CRT), or CRT-D/P, is not allowed within 6 months of implantation.

    ii. Implantable Cardioverter Defibrillator or pacemaker implantation is not allowed if implanted < 30 days prior to Screening (Visit 1).

    iii. CardioMems device is not allowed.

    l. Systolic blood pressure ≥ 160 mm Hg or < 90 mm Hg at Visit 1 or 2.

    m. Diastolic blood pressure ≥ 95 mm Hg at Visit 1 or 2.

  10. 6 Minute Walk Test (6MWT):

    1. Inability to perform the 6MWT for reasons unrelated to heart failure (eg, physical limitations, peripheral vascular disease).
    2. Distance walked in 6MWT (6MWD) < 100 m
  11. Pulmonary:

    1. Pulmonary disease requiring oxygen therapy;
    2. Severe chronic obstructive pulmonary disease; restrictive lung disease.
  12. Upper respiratory infection within 4 weeks of Screening (Visit 1).
  13. History of organ transplant.
  14. Viral syndrome with fever ≥101° Fahrenheit (patient may be reconsidered for enrollment 4 weeks following resolution of viral syndrome).
  15. History of human immunodeficiency virus or acquired immunodeficiency syndrome, history of hepatitis C virus, or immunosuppressed by medicines (corticosteroids, methotrexate, cyclophosphamide, cyclosporine).
  16. Presence of eGFR ≤ 30 mL/min/1.73 m2 using the Cockcroft Gault equation.
  17. Patients with life expectancy < 1 year.
  18. Documented Child Pugh B or C hepatic disease.
  19. Body Mass Index ≥ 40 kg/m2.
  20. Participation in any other clinical trial or registry within 30 days prior to Randomization (Visit 2).
  21. Hemoglobin ≤ 10 gm/dL.
  22. Prior history of malignancy.
  23. Prior history of gene transfer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03360448

Contact: Richard McCloskey, MD 858-461-1837 mac@renovatherapeutics.com

Sponsors and Collaborators
Renova Therapeutics

Responsible Party: Renova Therapeutics
ClinicalTrials.gov Identifier: NCT03360448     History of Changes
Other Study ID Numbers: RT-01-HF-REF
First Posted: December 4, 2017    Key Record Dates
Last Update Posted: January 9, 2018
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Blinded study - de-identified participant data to become available after completion of study.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Renova Therapeutics:
Gene Transfer

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases